Skip to Main Content

A federal jury in Seattle has awarded nearly $6 million to a former Biogen (BIIB) sales rep who claimed she was fired after complaining about being pressured to pursue off-label marketing for a multiple sclerosis treatment.

In her lawsuit, Danita Erickson contended that, in the fall of 2017, Biogen sought to ensure that Zinbryta was prescribed by a hematologist for a patient with aplastic anemia — a condition in which the body does not produce enough blood cells — and who was also on Medicare. However, the medicine was only approved for treating relapsing multiple sclerosis patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • Glad she raised a ruckus. Predatory marketing practices are all too common and leaving off-label descriptions to the pharmacy companies is leaving the fox in the chicken coop. Yeah, I know, their integrity is without question 🤪 Next …

Comments are closed.